Ocugen Diversifies Its Pipeline With New Cell Therapy Platform
Ocugen Inc (NASDAQ:OCGN) says it is diversifying its pipeline by introducing a Phase 3 cell therapy platform technology called NeoCart (autologous chondrocyte-derived neocartilage). Recently, the FDA granted a Regenerative Medicine Advanced Therapy (RMAT) designation to NeoCart to repair full-thickness lesions of the knee cartilage in adults. NeoCart is a three-dimensional tissue-engineered disc of…
Benzinga ·